Results 161 to 170 of about 53,085 (229)

Figure S1 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance

Chengxi Li, Yu‐Hsuan A. Chang, Minori Maki, Ikuko Omori, Naru Sato, Susumu Goyama, Toshio Kitamura, Yutaka Enomoto   +7 more
openalex   +1 more source

Bortezomib induces ROS-dependent mitochondrial apoptosis and suppresses SKP2 signaling in cutaneous T-cell lymphoma cells

Kirti Sathyananda Prabhu, Muhammad Suleman, Ummu Habeeba, Fareed Ahmad, Shilpa Kuttikrishnan, Jericha Miles Pamiloza Mateo, Gazala Anamangadan, Alvina Farooqui, Israa M. Salameh, Ajaz Ahmad Bhat, Shahab Uddin   +10 more
openalex   +1 more source

Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro. [PDF]

BMC Res Notes
Zhang M, Guiton PS.
europepmc   +1 more source

Synchronous Coexistence of JAK2 V617F-Positive Essential Thrombocythemia and IgG Kappa Multiple Myeloma in an Octogenarian Patient: A Case Report. [PDF]

Case Rep Med
Ribero-Vargas M, Ahumada-Córdoba F, Silva-Pérez NM, Ribero-Vargas D.   +3 more
europepmc   +1 more source

MAJESTEC-9: A PHASE 3 RANDOMIZED STUDY OF TECLISTAMAB MONOTHERAPY VS INVESTIGATOR’S CHOICE OF POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE OR CARFILZOMIB AND DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

Roberto Mina, Cyrille Touzeau, Vania Hungria, Ola Landgren, Divaya Bhutani, Wenming CHEN, Swarup KUMAR, Chakra P. Chaulagain, Meletios Athanasios Dimopoulos, Nizar BAHLIS, Senem Maral, Niels W.C.J. VAN DE DONK, Khalid Saja, Raphael Teipel, Miki ANDO, Dai WANG, Susan WROBLEWSKI, Priya Shah, Katherine M. Chastain, Jayr SCHMIDT FILHO   +19 more
openalex   +1 more source

Ixazomib- versus bortezomib-based proteasome inhibitor triplet regimens in older transplant-ineligible newly diagnosed multiple myeloma: A scoping review of real-world evidence [PDF]

Yan Wang, Sha Liu, Jiian‑qiing Mi
openalex   +1 more source

The SKP2-Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy. [PDF]

Cells
Zhang Y, Faruq O, Shrestha M, Alipoor SD, Chang H.   +4 more
europepmc   +1 more source

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience [PDF]

M. Da Via
openalex   +1 more source

Targeting the mevalonate pathway sensitizes multiple myeloma cells to bortezomib through induction of mitochondrial metabolic disruption. [PDF]

Cell Commun Signal
Li S, Hu N, Li X, Feng Y, Ran Y, Geng Z, Wang H, Wang J.   +7 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran

Neshaut Mashreghi Mohammadi, Behzad Fatemi, Mohammad Mahdi Raeis Zadeh, Shekoufeh Nikfar   +3 more
openalex   +1 more source